Moderna Spikevax COVID-19 Vaccine

Context:
- It can be administered as part of the 2024-2025 COVID-19 vaccination program, tailored to combat current variants.
- It can use mRNA sequences that instruct cells to produce the spike protein of SARS-CoV-2, stimulating an immune response.
- It can be administered as a single dose for many individuals, with additional doses recommended for immunocompromised persons.
- It can have mild side effects, such as injection site soreness, fatigue, headache, and muscle pain, which generally resolve within a few days.
- It can be available in healthcare facilities, pharmacies, and public health clinics.
- It can be recommended for ages six months and older, following public health guidelines on COVID-19 vaccination.
- ...
Example(s):
- an Updated Spikevax COVID-19 Vaccine 2024-2025, targeting recent SARS-CoV-2 variants.
- a Moderna mRNA-1273 COVID-19 Vaccine, the original Spikevax formulation used during the early stages of the COVID-19 pandemic.
- ...
Counter-Example(s):
- Moderna COVID-19 Vaccine mRNA-1273, the original Moderna formulation.
- Pfizer-BioNTech COVID-19 Vaccine, which is another mRNA-based COVID-19 vaccine but developed by Pfizer and BioNTech.
- Janssen COVID-19 Vaccine, a COVID-19 vaccine that uses an adenovirus vector rather than mRNA technology.
- Novavax COVID-19 Vaccine, a protein subunit COVID-19 vaccine that uses a different approach from mRNA technology.
See: mRNA Technology, COVID-19 Vaccine, SARS-CoV-2, Moderna, Vaccination Schedule.

References

_